TALENT Biotechs
Medical Cannabis Drugs
Company Overview
Snapshot
Founded in January 2014 by Moshe Yeshurun, TALENT Biotechs operated with 1–10 employees. The company was acquired by Kalytera Therapeutics in February 2017.
Business overview
TALENT Biotechs develops cannabidiol-based therapies, focusing on screening and leveraging patented pharmaceutical and medical technologies through clinical trials. The company specifically suggested the use of cannabidiol for the prevention and treatment of graft-versus-host disease, a significant cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation. Operating within the Health Tech & Life Sciences sector, the company serves the Pharmaceuticals market.
Strategic signal
In February 2017, TALENT Biotechs was acquired by Kalytera Therapeutics, a move that signals the consolidation within the medical cannabis and pharmaceutical sectors. This acquisition highlights the strategic interest in cannabidiol-based drug development and provides an exit for early-stage biotech companies focusing on niche therapeutic areas.
Log in to access full profile ›Company Intelligence Q&A
- What is TALENT Biotechs' primary focus?
- TALENT Biotechs develops cannabidiol-based therapies, particularly focusing on the prevention and treatment of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
- When was TALENT Biotechs founded?
- TALENT Biotechs was founded in January 2014.
- Who founded TALENT Biotechs?
- Moshe Yeshurun founded TALENT Biotechs.
- When was TALENT Biotechs acquired?
- TALENT Biotechs was acquired by Kalytera Therapeutics in February 2017.
- What is the status of TALENT Biotechs?
- TALENT Biotechs is currently Acquired (Inactive) by Kalytera Therapeutics, with the acquisition closing in February 2017.